Showing 491-500 of 9351 results for "".
Aesthetic Advances: New Technology
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/aesthetic-advances-new-technology/20160/Suneel Chilukuri, MD discusses the benefits of some of the new devices he’s using to improve outcomes for his aesthetic patients. He says BTL’s Emface offers him the ability to tighten and tone the facial muscles and lift neck muscles. He describes the benefits of the Sylfirm X RF microneedling systDermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility studyDermWireTV: Cosentyx for Kids; Anifrolumab for SLE, Tremfya in PsA at EULAR
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-for-kids-anifrolumab-for-sle-tremfya-in-psa-at-eular/19948/FDA has approved Cosentyx (secukinumab) from Novartis for patients as young as six years old. The 2nd Annual San Diego Dermatology Symposium kicks off as a live Virtual Experience next Friday. A post-hoc analysis of pooled data from the TULIP Phase 3 clinical trials shows that anifrolumab improvesNovel Treatments for Acne
https://practicaldermatology.com/topics/acne-rosacea/novel-treatments-for-acne/19761/Joshua Zeichner, MD discusses three new treatments now available in the acne treatment armamentarium. For patients with severe acne, a new low-dose isotretinoin in a micronized formulation allows for better absorption, even without food. Dr. Zeichner also discusses the benefits of a new topical retiAtopic Dermatitis: Rethinking the “Typical” Patient
https://practicaldermatology.com/topics/atopic-dermatitis/atopic-dermatitis-rethinking-the-typical-patient/19666/It's possible to make generalities about the experience of atopic dermatitis, but it's increasingly clear that there is no "typical" patient. Zelma Chiesa Fuxench, MD discusses the latest findings on the signs and symptoms of AD and the populations affected.What ’s the Best Approach to AK Therapies? Ask an Expert
https://practicaldermatology.com/topics/skin-cancer-photoprotection/what-s-the-best-approach-to-ak-therapies-ask-an-expert/19622/Rather than consider AK a specific disease, Vishal A. Patel, MD, FAAD says it can be viewed as a marker of disease, which culminates in SCC. In this edition of Ask an Expert with Adam Friedman, MD, about his philosophy of treatment, including long-term maintenance.The Aesthetic Revolution and the Rise of Cosmetic Dermatology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/watch-now-the-aesthetic-revolution-and-the-rise-of-cosmetic-dermatology/18350/No doubt the practice of dermatology has been shaped by the emergence of minimally invasive aesthetic interventions. This second of four episodes exploring the history of dermatology takes a look at the evolution of cosmetic dermatology.The Male Aesthetic Patient: Who He Is and What He Needs
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-male-aesthetic-patient-who-he-is-and-what-he-needs/18701/Baby boomer men aren't necessarily driving the growth in male aesthetics. Terrence Keaney, MD says that millennial men in their 30s and 40s are most likely to seek treatments. In the initial consultation, education is essential so men understand the treatments offered and recognize that you understaCellfina Cleared, Finacea Foam Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-cellfina-cleared-finacea-foam-approved/18866/The FDA has cleared Cellfina (Ulthera Inc./Merz Aesthetics, Inc.) to treat cellulite, with results lasting for up to 2 years. Finacea Foam (azelaic acid, Bayer Dermatology) is approved for Rosacea, and Almirall invests in Suneva Medical, maker of Bellafill. Also in this edition, a look at the data oPsoriasis PACT Launches with Pfizer Support
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-psoriasis-pact-launches-with-pfizer-support/19028/New Services Launched to Support Psoriasis Patients, Dermatologists; New Developments in Valeant's Bid for Allergan; Promising Results for a Topical for Hyperhidrosis